Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government price setting, which would become effective on January 1, 2028.

The approval is the 14 th for Keytruda, extending its use into a tenth ... for Opdivo in second-line HCC after it became clear the EMA would not accept the data that backed its US approval.

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

China National Medical Products Administration (NMPA) has approved MSD’s KEYTRUDA for use in conjunction with platinum-containing chemotherapy as a neoadjuvant treatment and as a single agent ...

The EMA has started its review of the PD ... $21 billion mega-blockbuster Keytruda, meanwhile, was approved by the FDA for relapsed endometrial cancer patients with MSI-H or dMMR mutations last ...